Computer-Aided Drug Design Identifies Amentoflavone as Novel RAB10 Inhibitor: Unlocking New Horizons in Hepatocellular Carcinoma Therapy

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and is often associated with a poor prognosis, contributing significantly to cancer-related mortalities. It has been established that RAB10, a member of the RAS family, is overexpressed in HCC and plays an oncogenic role in the emergence of HCC, and developing medications that target it may offer a fresh approach to the disease's management. Therefore, a computational approach was employed to identify potential novel RAB10 inhibitors, and 2569 natural compounds were looked into for this. Initially, 10 compounds were identified by virtual screening and molecular docking to have the highest binding affinities (−9.6 to −10.1 kcal/mol) to the active site of RAB10, where 8 were deemed to meet the necessary criteria for becoming a drug-like substance. Following ADMET analysis, Amentoflavone, among the 8 substances, showed a considerable pharmacokinetics index without any associated toxicity. Amentoflavone was found to form both covalent and non-covalent interactions with the active residues of RAB10, essential for inhibiting its activity. LYS154, ALA153, and LYS22 amino acids of RAB10 were found to interact with the Amentoflavone via the generation of three intermolecular H-bonds. The drug-protein combination, which supports maintaining its structural stability and stiffness, demonstrates structural compactness and minimal conformational fluctuation, according to molecular dynamics simulation. Molecular Mechanics Poisson-Boltzmann Surface Area analysis further confirmed the stable binding of Amentoflavone inside the binding pocket of RAB10. These findings hypothesize that Amentoflavone might be a potential RAB10 inhibitor, which would increase HCC's therapeutic prospects. Received: 18 October 2024 | Revised: 28 March 2025 | Accepted: 20 May 2025 Conflicts of Interest The authors declare that they have no conflicts of interest to this study. Data Availability Statement The data that support this work are available upon reasonable request to the corresponding author. The final outputs of all the analyses are documented in the main manuscript. Author Contribution Statement Md. Anayet Ullah: Methodology, Software, Formal analysis, Writing – original draft, Visualization. Priya Paul: Software, Formal analysis, Writing – original draft, Visualization. Sadia Afrin Runa: Formal analysis, Writing – original draft. Fatema Tuz Johura: Formal analysis, Writing – original draft. Mahafujul Islam Quadery Tonmoy: Conceptualization, Methodology, Software, Validation, Formal analysis, Writing – review & editing, Visualization. Md. Shahriar Kabir Shakil: Resources, Writing – review & editing. Rumana Rashid: Writing – review & editing. Md. Mizanur Rahaman: Resources, Writing – review & editing. Newaz Mohammed Bahadur: Conceptualization, Validation, Investigation, Resources, Writing – review & editing, Supervision.

Authors

Institutions

Publication Details

Journal
Medinformatics
Published
2025-06-02
DOI
https://doi.org/10.47852/bonviewmedin52024568
Citations
1
Primary Topic
Biological Activity of Diterpenoids and Biflavonoids
Type
article
Field-Weighted Citation Impact
0.81
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Computer-Aided Drug Design Identifies Amentoflavone as Novel RAB10 Inhibitor: Unlocking New Horizons in Hepatocellular Carcinoma Therapy

Mahafujul Islam Quadery Tonmoy, Priyanka Paul, Rumana Rashid, Md. Mizanur Rahaman et al.
1 citations
Medinformatics
Biological Activity of Diterpenoids and Biflavonoids
0.81
article

Computer-Aided Drug Design Identifies Amentoflavone as Novel RAB10 Inhibitor: Unlocking New Horizons in Hepatocellular Carcinoma Therapy

Mahafujul Islam Quadery Tonmoy, Priyanka Paul, Rumana Rashid, Md. Mizanur Rahaman, Md Shakil, Newaz Mohammed Bahadur, Md. Anayet Ullah, Fatema Tuz Johura, Sadia Afrin Runa
article en
1 citations

Abstract

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and is often associated with a poor prognosis, contributing significantly to cancer-related mortalities. It has been established that RAB10, a member of the RAS family, is overexpressed in HCC and plays an oncogenic role in the emergence of HCC, and developing medications that target it may offer a fresh approach to the disease's management. Therefore, a computational approach was employed to identify potential novel RAB10 inhibitors, and 2569 natural compounds were looked into for this. Initially, 10 compounds were identified by virtual screening and molecular docking to have the highest binding affinities (−9.6 to −10.1 kcal/mol) to the active site of RAB10, where 8 were deemed to meet the necessary criteria for becoming a drug-like substance. Following ADMET analysis, Amentoflavone, among the 8 substances, showed a considerable pharmacokinetics index without any associated toxicity. Amentoflavone was found to form both covalent and non-covalent interactions with the active residues of RAB10, essential for inhibiting its activity. LYS154, ALA153, and LYS22 amino acids of RAB10 were found to interact with the Amentoflavone via the generation of three intermolecular H-bonds. The drug-protein combination, which supports maintaining its structural stability and stiffness, demonstrates structural compactness and minimal conformational fluctuation, according to molecular dynamics simulation. Molecular Mechanics Poisson-Boltzmann Surface Area analysis further confirmed the stable binding of Amentoflavone inside the binding pocket of RAB10. These findings hypothesize that Amentoflavone might be a potential RAB10 inhibitor, which would increase HCC's therapeutic prospects. Received: 18 October 2024 | Revised: 28 March 2025 | Accepted: 20 May 2025 Conflicts of Interest The authors declare that they have no conflicts of interest to this study. Data Availability Statement The data that support this work are available upon reasonable request to the corresponding author. The final outputs of all the analyses are documented in the main manuscript. Author Contribution Statement Md. Anayet Ullah: Methodology, Software, Formal analysis, Writing – original draft, Visualization. Priya Paul: Software, Formal analysis, Writing – original draft, Visualization. Sadia Afrin Runa: Formal analysis, Writing – original draft. Fatema Tuz Johura: Formal analysis, Writing – original draft. Mahafujul Islam Quadery Tonmoy: Conceptualization, Methodology, Software, Validation, Formal analysis, Writing – review & editing, Visualization. Md. Shahriar Kabir Shakil: Resources, Writing – review & editing. Rumana Rashid: Writing – review & editing. Md. Mizanur Rahaman: Resources, Writing – review & editing. Newaz Mohammed Bahadur: Conceptualization, Validation, Investigation, Resources, Writing – review & editing, Supervision.

MedinformaticsVol. 2(4)
Gopalganj Science and Technology University (BD), Noakhali Science and Technology University (BD), Primeasia University (BD)
Openalex Percentile: Top 27%
Biological Activity of Diterpenoids and Biflavonoids
0.81
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.